Abstract
Single-agent immunotherapy has improved outcomes for patients with cancer, but only a minority of patients respond, necessitating investigation of combinations of immunotherapy agents. In this issue of Cancer Immunology Research, Milling and colleagues show that neoadjuvant therapy with an intratumoral stimulator of interferon genes agonist combined with systemic IL2 and anti-PD-1 results in clearance of lung metastases mediated by natural killer cells in mouse models of triple-negative breast cancer.See related article by Milling et al., p. 26. (4).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
